Drug Patents owned by Optinose Us Inc

1. List of Xhance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8522778 OPTINOSE US INC Nasal devices
May, 2022

(8 months ago)

US8327844 OPTINOSE US INC Nasal delivery method
Oct, 2023

(7 months from now)

US7975690 OPTINOSE US INC Nasal devices
Dec, 2025

(2 years from now)

US10124132 OPTINOSE US INC Nasal delivery
Mar, 2027

(4 years from now)

US10076615 OPTINOSE US INC Nasal delivery
Jul, 2029

(6 years from now)

US8550073 OPTINOSE US INC Nasal delivery
Oct, 2029

(6 years from now)

US8978647 OPTINOSE US INC Nasal delivery
Dec, 2030

(7 years from now)

US10252010 OPTINOSE US INC Nasal delivery devices
Feb, 2031

(8 years from now)

US11033696 OPTINOSE US INC Nasal delivery devices
May, 2033

(10 years from now)

US10179216 OPTINOSE US INC Nasal delivery devices
Jul, 2033

(10 years from now)

US10478574 OPTINOSE US INC Nasal administration
Nov, 2033

(10 years from now)

US10076614 OPTINOSE US INC Nasal delivery devices
Oct, 2034

(11 years from now)

US10300229 OPTINOSE US INC Nasal delivery devices
Jul, 2035

(12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in